Policy and regulation

NICE approves stomach tumour treatment

2009-09-23T11:10:00

Sunitinib has been recommended by NICE for gastro-intestinal stromal tumours (Gists) after a pricing deal with maker Pfizer.

Source: MAXPPP

Sunitinib has been recommended by NICE for gastro-intestinal stromal tumours after a pricing deal with maker Pfizer.

You need to be a subscriber to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All HSJ news by sector, topic & region
  • Breaking News announcements
  • App for mobile and offline reading
  • Comment and Daily Insights newsletters
  • Regional roundup newsletters
  • 10 expert briefings every fortnight (Premium only)
  • Unrestricted access to ‘Ask HSJ’ - AI assistant - AI assistant (Premium only)

Subscribe

to HSJ

Already a subscriber? Sign into your account here